Thursday, August 13, 2009

New Immune-suppressing Treatment

Multiple Sclerosis Successfully Reversed In Mice: New Immune-suppressing Treatment Forces The Disease Into Remission

ScienceDaily (Aug. 12, 2009) — A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder in mice, and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal.

MS is an autoimmune disease in which the body's own immune response attacks the central nervous system, almost as if the body had become allergic to itself, leading to progressive physical and cognitive disability.

The new treatment, appropriately named GIFT15, puts MS into remission by suppressing the immune response. This means it might also be effective against other autoimmune disorders like Crohn's disease, lupus and arthritis, the researchers said, and could theoretically also control immune responses in organ transplant patients. Moreover, unlike earlier immune-suppressing therapies which rely on chemical pharmaceuticals, this approach is a personalized form of cellular therapy which utilizes the body's own cells to suppress immunity in a much more targeted way.

GIFT15 was discovered by a team led by Dr. Jacques Galipeau of the JGH Lady Davis Institute and McGill's Faculty of Medicine. The results were published August 9 in the prestigious journal Nature Medicine.

GIFT15 is composed of two proteins, GSM-CSF and interleukin-15, fused together artificially in the lab. Under normal circumstances, the individual proteins usually act to stimulate the immune system, but in their fused form, the equation reverses itself.

"You know those mythical animals that have the head of an eagle and the body of a lion? They're called chimeras. In a lyrical sense, that's what we've created," said Galipeau, a world-renowned expert in cell regeneration affiliated with the Segal Cancer Centre at the Jewish General and McGill's Centre for Translational Research. "GIFT15 is a new protein hormone composed of two distinct proteins, and when they're stuck together they lead to a completely unexpected biological effect."

This effect, explained Galipeau, converts B-cells -- a common form of white blood cell normally involved in immune response -- into powerful immune-suppressive cells. Unlike their better-known cousins, T-cells, naturally-occurring immune-suppressing B-cells are almost unknown in nature and the notion of using them to control immunity is very new.

"GIFT15 can take your normal, run-of-the-mill B-cells and convert them -- in a Superman or Jekyll -Hyde sort of way -- into these super-powerful B-regulatory cells," Galipeau explained. "We can do that in a petri dish. We took normal B-cells from mice, and sprinkled GIFT15 on them, which led to this Jekyll and Hyde effect.

"And when we gave them back intravenously to mice ill with multiple sclerosis, the disease went away."

MS must be caught in its earliest stages, Galipeau cautioned, and clinical studies are needed to test the treatment's efficacy and safety in humans. No significant side-effects showed up in the mice, he said, and the treatment was fully effective with a single dose.

"It's easy to collect B-cells from a patient," he added. "It's just like donating blood. We purify them in the lab, treat them with GIFT15 in a petri dish, and give them back to the patient. That's what we did in mice, and that's what we believe we could do in people. It would be very easy to take the next step, it's just a question of finding the financial resources and partnerships to make this a reality."


Source:

  • http://www.sciencedaily.com/releases/2009/08/090811143725.htm


Thank you to my friend, Amanda, for alerting me to this article. This would be even better than an oral pill to eliminate the syringe administration of medicine. :) Technology and science is a surprising and every changing thing - I am always keeping my fingers crosses for good news!


Thursday, May 14, 2009

Yippie - Copay change!

I had a nice surprise on Saturday (5/9) when I went and picked up my last 30-day Copaxone refill. The pharmacist scanned my Rx and told me my total was $30. With a quizzical tone I asked her "$30 is my total, that is it.. just $30?" because, if you remember, I had been paying $150 for a 30-day supply. She explained how so many people had complained to Catalyst, Beaumont's Pharmacy Benefit Manager (PBM), about the copay cost for the medications in the same tier as Copaxone that they changed the copay.

I was so thrilled that I was not the only one the complained.. and that our complaints had been heard and addressed. Not to say I don't appreciate the beneficial copay change, but I miss when I was able to get the 3 month supply for $50 before Beaumont changed insurance companies.

Thursday, May 7, 2009

Say 'good-bye' to needles?!

Significant research announcements during MS Week

30 Apr 2009

This year’s MS Week is set to be one of the most memorable of awareness weeks for multiple sclerosis (MS) after a number of significant drug announcements.

Scientists specialising in MS and presenting at the annual American Academy of Neurology convention in Seattle have reported research findings that take the field of MS treatments to a “new dawn”.

Head of Research at the MS Society, Dr Lee Dunster, said: “This week’s announcements herald a step change in treatment options for people with the most prevalent form of MS at the time of diagnosis.

“News of the development of two oral therapies for MS marks a new dawn and this could be a huge step forward for people who currently have to inject their treatments.

“We are looking at treatments that could be available on the NHS by the end of next year that will make a real difference to people’s lives.”

Today (Thursday), Professor Gavin Giovannoni from Queen Mary, University of London announced trial results of the drug cladribine, which may become the first effective treatment available in tablet form for relapsing remitting MS.

The Merck Serono drug, used in leukaemia for a number of years, was shown in latest studies in more than 1,300 people to bring about a 58 per cent reduction in yearly relapse rates compared to placebo.

There was also a 30 per cent reduction in progression of disability as measured by the Expanded Disability Status Scale (EDSS) and a reduction in lesion activity (as measured by MRI) in participants taking up to 30 cladribine tablets over the two years.

Meanwhile, Novartis announced news yesterday (Wednesday) of the latest results of their oral MS therapy, FTY720 (fingolimod).

The Phase III results showed that in more than 1,200 people with relapsing remitting MS the drug brought about a 52 per cent reduction in yearly relapse rates compared to beta interferon.

The treatment has yet, however, to show potential to slow progression of disability.

Source:
  • http://www.mssociety.org.uk/go.rm?id=25858

Monday, March 16, 2009

December '08 Test Results

I wanted to post a quick follow-up to my last posting.

As I assumed, Casey was able to translate my lab results from all the blood drawn back in December. Everything is fine and in the 'optimal' range :)

Tuesday, March 3, 2009

3/3/09

I had my second check up today with the same neurologist from December 2008, Dr. Alka Shah. The appointment was originally scheduled for 2/3/09 but for some reason it was moved to today.

Today's appointment went a lot better than the one in December. After that visit I was so temped to find a different neurologist; however, I said I was going to give Dr. Shah one more chance to redeem herself before I started looking for a different doctor.

I have to express that there was an aspect about the visit that was annoying. My appointment was at 12:15pm and I acknowledge that most of the time afternoon doctor visits are running late but.... I wasn't called into a room until 1:10pm where I remained for quite some time and wasn't acknowledged by the neurologist until 2:10pm. I was not actually seen until 2:35pm. I am, unfortunately, not exaggerating. The doctor had peaked her head in (at 1:10pm) and said she was running a bit late.... hmm, you think? Once it was my turn to be seen, I was with the doctor for 8 minutes maximum. I thought, "I should have kept the $15 copay instead of paying it." I had more than enough time to think of questions, if I had any, and then I completely forgot to to ask about the lab results from all the blood they took back in Dec. I usually try to write my questions down so I don't forget but I thought I would remember. I should have known better. Then again I shouldn't have had to ask about the results as I thought that was one of the reasons for my appointment. I was a bit irritated, but that isn't going to do me any good. I called this morning and requested a copy of the lab results - Casey can translate the medical jargon into English for me :)

When the lady making appointments asked what time I wanted on June 9th, I told her 'as early as possible so I didn't have to wait as long as I did today'.

Anyway, everything check out.. nothing new.

Thursday, January 22, 2009

New Needle Gauge

As of 12/26/2008, Teva Neuroscience, the manufacturing company for Copaxone, launched a new, thinner, 29-gauge pre-filled syringe for Copaxone.

The company reported that a recent survey of 562 MS patients found the new thinner needle was significantly preferred by 77 percent of patients over the previous 27-gauge needle, and that approximately two out of three (66 percent) participants experienced less pain while using the thinner needle and almost half of the participants (49 percent) had a better experience dealing with injection-site reactions.


My most recent refill of Copaxone contained the new gauged syringes so I was happy about that. Today was the second time I used the 29-gauge syringes: yesterday's injection site was in the upper portion of my right arm and today's site was the upper right portion of my hip. It may be the fact of simply knowing that needle's gauge is smaller causes me to think the injection don't seem to hurt as much or what not (but they still, unfortunately, sting) but I am happy to know that the company is trying to improve the comfort factor to those administering medication via syringe.

For the purpose of this entry/post, I took a few side-by-side comparison pictures of the 27 and 29-gauge syringes this morning, however the images were too blurry. I assume my want to get closer than possible pictures to illustrate the difference is not feasible with my camera. Oh well, it's the thought that counts right?! :)

FYI-If you didn't already know, the higher the gauge, the thinner the needle.


Sources:
  1. http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=596
  2. http://www.seattle.dbusinessnews.com/shownews.php?newsid=173403&type_news=past